Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MSB | Sydney | AUD | Delayed | |
MESO | NASDAQ | USD | Real-time | |
MEOBF | OTC Markets | USD | Delayed |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Buy | Neutral | Neutral | Sell |
Technical Indicators | BUY | BUY | Strong Buy | BUY | Strong Buy |
Summary | Buy | Buy | Buy | Neutral | Neutral |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Three Inside Up | 1H | Current | |||
Three Inside Up | 5H | Current | |||
Three Inside Up | 1D | Current | |||
Three Inside Up | 1W | Current | |||
Completed Patterns | |||||
Tri-Star Bearish | 15 | 1 | Mar 28, 2024 18:15 | ||
Tri-Star Bullish | 1M | 4 | Nov 23 | ||
Tri-Star Bullish | 30 | 7 | Nov 24, 2023 14:30 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
Sydney | 0.785 | 0.780 | 0.785 | 1,805,699 | +1.29% | AUD | |||
NASDAQ | 5.110 | 5.050 | 5.100 | 267,553 | +2.00% | USD | |||
OTC Markets | 0.600 | 0.000 | 0.000 | 0 | +0.00% | USD |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
IAG | 169.80 | 187.90 | 163.55 | +9.10 | +5.66% | 35.30M | 18/04 | ||
Rolls-Royce Holdings | 402.50 | 406.71 | 398.30 | +1.10 | +0.27% | 34.65M | 18/04 | ||
EasyJet | 530.00 | 547.00 | 526.40 | +11.80 | +2.28% | 15.43M | |||
Lloyds Banking | 51.00 | 51.30 | 50.62 | +0.58 | +1.15% | 95.48M | |||
BP | 512.40 | 515.10 | 508.20 | -4.40 | -0.85% | 36.63M | 18/04 | ||
Ocado | 350.00 | 350.50 | 3.48 | +1.80 | +0.52% | 3.54M | |||
Centamin | 128.10 | 129.50 | 120.10 | -1.60 | -1.23% | 10.66M | |||
Barclays | 183.98 | 183.98 | 181.14 | +4.04 | +2.25% | 72.90M | |||
HSBC | 644.60 | 645.60 | 637.60 | +8.50 | +1.34% | 44.84M | |||
BAE Systems | 1,287.00 | 1,316.50 | 1,272.50 | -33.00 | -2.50% | 11.50M |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Read MoreAre you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review